

CLINICAL REPORT

Confined placental mosaicism involving multiple de novo copy number variants associated with fetal growth restriction: A case report

Giulia F. Del Gobbo^{1,2} | Victor Yuan^{1,2} | Wendy P. Robinson^{1,2} ¹BC Children's Hospital Research Institute, Vancouver, Canada²Department of Medical Genetics, University of British Columbia, Vancouver, Canada**Correspondence**Wendy P. Robinson, BC Children's Hospital Research Institute, 950 W 28th Ave, Vancouver, Canada, V5Z 4H4.
Email: wrobinson@bcchr.ca**Funding information**

Canadian Institutes of Health Research, Grant/Award Number: F16-04459

Abstract

The presence of multiple large (>1 Mb) copy number variants (CNVs) in non-malignant tissue is rare in human genetics. We present a liveborn male with a birth weight below the first percentile associated with placental mosaicism involving eight 2.4–3.9 Mb de novo duplications. We found that the duplications likely co-localized to the same cells, were mosaic in the placenta, and impacted maternal and paternal chromosomes. In addition, 27.4 Mb and 240 genes were duplicated in affected cells, including candidate placental genes *KISS1* and *REN*. We ruled out involvement of homologous recombination-based mechanisms or an altered epigenome in generating the CNVs. This case highlights the diversity of genetic abnormalities in the human placenta and the gaps in our knowledge of how such errors arise.

KEYWORDS

CNV, de novo, fetal growth restriction, mosaicism, placenta

1 | INTRODUCTION

Copy number variants (CNVs) are an important source of genetic variation in humans. The majority of CNVs are small; only about 3% of healthy adults carry a large rare CNV >1 Mb (Collins et al., 2020). This rate is higher in populations with congenital abnormalities, developmental delay, or neurodevelopmental disorders (Girirajan et al., 2011). The occurrence of several large rare CNVs in one individual is extremely rare even in clinical populations. Large chromosomal aberrations are common in early development (van Echten-Arends et al., 2011), however, abnormal embryos are typically not viable unless mosaicism with a normal cell population occurs and the abnormal cells are mainly restricted to extraembryonic tissues (Lestou & Kalousek, 1998). This confined placental mosaicism (CPM) may impact placental function and lead to poor pregnancy outcomes like fetal growth restriction (FGR) (Lestou & Kalousek, 1998). We report a novel

case of CPM involving eight 2.4–3.9 Mb de novo duplications associated with FGR. We explore the potential of these CNVs to explain FGR and possible mechanisms of origin.

2 | MATERIALS AND METHODS

Ethics approval was obtained from the University of British Columbia/Children's and Women's Health Centre of B.C. Research Ethics board (H17-01545). The case (PM324) was identified from a cohort of placentas from control and small-for-gestational age (SGA; birth weight <10th percentile) pregnancies profiled for CNVs using the Infinium Omni2.5–8 BeadChip array (Illumina, San Diego, USA) (Del Gobbo et al., 2021). Due to case deidentification, minimal clinical data were available. The case was ascertained due to a prenatal diagnosis of symmetric FGR of unknown cause (Lausman et al., 2013). The mother

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2021 The Authors. *American Journal of Medical Genetics Part A* published by Wiley Periodicals LLC.

was of normal BMI and did not smoke. A male infant was born at 40 weeks gestation with a birth weight of 2600 g (<1st percentile, adjusted for sex and gestational age; Kramer et al., 2001). The course of the pregnancy was otherwise normal. The placenta was <3rd percentile in weight, and histological exam showed mildly immature villi for the gestational age, but was otherwise unremarkable.

Samples of chorionic villi (vil), amnion, and chorion were obtained from four distinct placental cotyledons (sites 1–4), in addition to umbilical cord. Part of each sample of chorionic villi was enzymatically digested to produce samples enriched for the trophoblast and mesenchyme of the villi (Robinson et al., 2010). In addition to two samples (vil1, vil4) previously analyzed (Del Gobbo et al., 2021), DNA from vil2 and vil3 was screened for CNVs using the Omni2.5–8 array (Del Gobbo et al., 2021). Genotyping of microsatellite loci within the duplicated regions in all available tissues was used to confirm array findings, determine parental origin, and assess level of mosaicism (Robinson et al., 2010) (Appendix S1; Table S1). DNA from maternal blood was used to assess maternal genotype.

Imprinted genes, placental imprinted differentially methylated regions (DMRs), and genes with elevated placental expression were identified as previously described (Del Gobbo et al., 2021). Coordinates of segmental duplications and repeat DNA were accessed from the genomicSuperDups and RepeatMasker tables from the UCSC Browser; fragile sites from the HumCFS database (Kumar et al., 2019); and placental partially methylated domains (PMDs), blocks of low-methylated DNA characteristic of the placental epigenome, as previously described (Yuan et al., 2021). Enrichment of elements near breakpoints was assessed by permutation tests using the *regioneR* package in R, with 10,000 permutations selecting random non-overlapping regions of the same size in the genome.

To determine potential alterations in DNA methylation (DNAm), DNA from vil1 and vil4 were assessed on the Infinium MethylationEPIC BeadChip (Illumina), along with chorionic villus samples from 19 healthy term pregnancies. Data were processed as described (Yuan et al., 2021) and methylation beta (β) values were extracted for DNAm analysis.

3 | RESULTS

We previously identified eight 2.4–3.9 Mb interstitial duplications in seven chromosomes in a placental chorionic villus sample (vil1) (Del

Gobbo et al., 2021) (Table 1). Microarray assessment of three additional samples from the placenta (vil2–vil4; Figure 1(a)) suggested absence of these or other large CNVs. Microsatellite genotyping of all extraembryonic samples confirmed that the proportion of cells containing each independent duplication was similar (Table S2), therefore, we concluded that they were likely de novo and co-occurred in the same cells. Averaging estimates across all loci tested indicated that vil1 had ~60% abnormal cells, with the trophoblast more affected than the sample enriched for mesenchyme (72% and 22%, respectively; Figure 1(b)). Additionally, low levels of abnormal cells (<10%) were estimated in site 3, near to site 1 (Figure 1(a), (b)). The amnion and umbilical cord, most similar in developmental origin to fetal tissues, were unaffected, suggesting that the duplications were likely confined to the placenta (Figure 1(b)). One duplication involved the maternal chromosome, four involved paternal chromosomes, and three were uninformative for parental origin (Table 1).

Among the eight CNVs, >27.4 Mb was duplicated (Table 1). The CNVs were absent from population controls (Collins et al., 2020; MacDonald et al., 2014), and did not overlap known microduplication syndrome loci. One pathogenic and seven likely pathogenic duplications overlapped four of the CNVs (1q32.1, 5q35.1, 7q11.21q11.22, 11p11.2) by at least 50% (Table S3)(Firth et al., 2009; Landrum et al., 2018; Olson et al., 2012). Of the associated cases, only one, with a likely pathogenic 1.17 Mb duplication in 5q35.1, showed evidence of poor growth (Table S3). In total, 240 genes were involved in the duplications (Table 1), 40 of which were disease-associated in OMIM, and several are highly expressed in placenta (*KISS1*, *REN*, *LARGE2*, *MNTR1B*, and *VSTM5*). One duplication overlapped placental-specific imprinted DMRs near *PRDM11* and *MAPK8IP1*.

To explain the simultaneous occurrence of eight duplications, we searched for features that might be enriched around (<100 kb) the 16 CNV breakpoints. These were not associated with chromosome fragile sites, early- or late-replicating regions, or placental PMDs ($p > 0.05$). There were no pairs of segmental duplications near CNV breakpoints, nor was there enrichment of segmental duplications or Alu, LINE-1, or LTR repetitive elements ($p > 0.05$).

To explore whether an unusual epigenetic profile may have contributed to genomic instability or impacted placental function, we compared DNAm in vil1 (containing CNVs) to vil4 (balanced) and 19 term controls. DNAm in vil1 was not distinct based on genome-wide principal components analysis, sample pairwise correlations,

TABLE 1 Eight large duplications present in a mosaic state in case PM324 placenta

Genomic coordinates (hg19)	Cytogenetic band	Size (Mb)	Parental chromosome	Genes (N)	Genes of interest
Chr1:200,478,352-204,413,297	1q32.1	3.93	Maternal	71	<i>KISS1</i> , <i>REN</i> , <i>KDM5B</i>
Chr5: 169,133,115-172,752,205	5q35.1	3.62	Paternal	31	
Chr6: 66,855,754-69,301,518	6q12	2.45	Unknown	0	
Chr7: 65,791,671-69,249,095	7q11.21-q11.22	3.46	Unknown	15	
Chr8: 92,757,374-96,311,905	8q21.3-q22.1	3.55	Unknown	29	
Chr11: 43,851,111-47,385,923	11p11.2	3.53	Paternal	53	<i>LARGE2</i>
Chr11: 90,310,352-93,636,999	11q14.3-q21	3.33	Paternal	16	<i>MTNR1B</i> , <i>VSTM5</i> , <i>PRDM11</i> , <i>MAPK8IP1</i>
Chr17: 48,475,076-52,011,849	17q21.33-q22	3.54	Paternal	25	




FIGURE 1 Estimated percentage of cells carrying the eight duplications in available samples from PM324 placenta and associated fetal membranes. (a) Schematic of tissues sampled, including chorionic villi (vil), enzymatically separated trophoblast (tro) and mesenchyme (mes) from villi, chorion (ch), and amnion (am) from four distinct locations in the placenta (sites 1–4), and umbilical cord. Circles are not to scale. (b) Mean percentage of abnormal cells in each sample calculated from all informative microsatellite loci tested within the duplications. Error bars indicate SD

overall methylation β -value distribution, nor DNAm of PMDs (Figure S1). On average, DNAm in the duplications tended to be lower in vil1 compared to vil4 and term controls (Figure S1c-d; Table S4).

4 | DISCUSSION

We describe the first example of multiple large (>1 Mb) de novo duplications identified in the placenta from an infant with FGR. The duplications were mosaic, impacted localized regions of the placenta, and involved both parental chromosomes, indicating a post-zygotic origin. As levels were highest in trophoblast, and because enzymatically separated mesenchyme retains up to 50% trophoblast cells (Yuan et al., 2021), we presume the duplications are confined to the trophoblast. Additionally, the consistency of the level of mosaicism among duplications within individual samples suggests that they arose simultaneously in one cell early in development.

Chorionic villus trees grow clonally from a few precursors shortly after implantation (Castellucci et al., 1990; Peñaherrera et al., 2012). Because abnormal cells were present in two separate sampling sites, representing two different cotyledons, but absent from others, the mutational event most likely occurred in a trophectoderm cell after blastocyst formation but prior to primary villus formation. The apparent patchy distribution of mosaicism is expected given the placental

tree structure, and does not allow inference of any selective growth advantage/disadvantage of the abnormal cells.

The duplications may have impacted placental function and thereby fetal growth, as some relevant genes were duplicated, including *KISS1*, involved in trophoblast migration and angiogenesis and over-expressed in preeclampsia (Bilban et al., 2004; Francis et al., 2014; Zhang et al., 2011), and *REN*, dysregulated in preeclampsia and involved in trophoblast proliferation (Lumbers et al., 2019). One paternal duplication involved polymorphic, maternal-imprinted placental DMRs associated with *PRDM11* and *MAPK8IP1* (Hanna et al., 2016), and one duplication overlapped a likely pathogenic CNV in a patient with poor growth. Despite these lines of evidence, much of the placenta was chromosomally normal, therefore, it remains possible that other unidentified factors contributed to the severity of FGR in this case.

The cause of this unusual multi-CNV event is unclear. Lack of evidence for large homologous sequences around CNV breakpoints argues against homologous recombination-based mechanisms. DNAm in vil1 containing the duplications was unaltered, although this does not exclude that epigenetic defects early in development may have been involved, as we tested placental tissue after birth. Due to limited microarray probe density, we could not determine exact coordinates of the CNV breakpoints to perform sequence analysis to identify signatures of non-homologous, replication-based mechanisms of CNV origin.

The occurrence of eight large duplications of consistent size is nonetheless remarkable, and there are few similar reports. Chromoanagenesis may generate multiple large CNVs, however, the limited number and dispersal of the present duplications across several chromosomes does not fit with known molecular features of chromoanagenesis (Zepeda-Mendoza & Morton, 2019). Recently, the presence of 4–9 de novo CNVs, mainly duplications >100 kb, was reported in 5 of 60,000 individuals from a clinical population (Liu et al., 2017). These multiple de novo CNVs were associated with replication-based mechanisms, evidenced by short microhomologies and microhomeologies near breakpoints, and mosaicism was not observed (Liu et al., 2017). Another case of an SGA infant was reported with a placenta carrying 3 “partial trisomies”: a 22 Mb dup(6)(p22.3pter), a 5.8 Mb dup(9)(q34.13), and a 22 Mb dup(21)(q21.2qter), present in only one of five placenta biopsies (Zamani Esteki et al., 2019). The alterations were all terminal, in contrast to the smaller interstitial duplications we identified.

This case is unique and relevant to the study of the diversity of genomic abnormalities in humans. Because mosaic abnormalities may persist in the placenta even when the fetus is normal, abnormalities such as this one, although rare, may be more prevalent in placental tissues. For example, this case was found among 54 SGA placentas screened for CNVs (Del Gobbo et al., 2021). Future studies profiling CNVs and other genomic alterations in the placenta should consider testing multiple distinct regions to further explore such mosaicism. With increasing use of non-invasive testing to detect fetal genomic abnormalities from placental DNA in maternal blood, it is important to understand the diversity of genomic abnormalities in the placenta,

how often they may be confined to extraembryonic tissues, and their incidence in normal and uncomplicated pregnancies.

ACKNOWLEDGMENTS

We thank the participant for the generous donation of samples. We thank Kristal Louie for case recruitment, Ruby Jiang and Dr Maria Peñaherrera for contributions to placental sampling and DNA extraction, Ishira Bharadhwaj for assistance in PCR optimization, Dr Michael Kobor for the use of Illumina DNAm microarray facilities, and the Centre for Applied Genomics at the Hospital for Sick Children for running the SNP microarray. We owe additional thanks to Dr Maria Peñaherrera for discussions of the case and analysis, assistance troubleshooting assays and running the DNAm microarray. This research was supported by a CIHR project grant to W.P.R. [F16-04459]. W.P.R. receives salary support through an investigatorship award from the BC Children's Hospital Research Institute, and G.F.D.G. and V. Y. receive support from CIHR Doctoral Fellowships.

CONFLICT OF INTEREST

The authors have no conflict of interest to declare.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Wendy P. Robinson  <https://orcid.org/0000-0002-2010-6174>

REFERENCES

- Bilban, M., Ghaffari-Tabrizi, N., Hintermann, E., Bauer, S., Molzer, S., Zoratti, C., ... Desoye, G. (2004). Kisspeptin-10, a KiSS-1/metastin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblasts. *Journal of Cell Science*, 117(Pt 8), 1319–1328. <https://doi.org/10.1242/jcs.00971>
- Castellucci, M., Schepe, M., Scheffen, I., Celona, A., & Kaufmann, P. (1990). The development of the human placental villous tree. *Anatomy and Embryology*, 181(2), 117–128. <https://doi.org/10.1007/BF00198951>
- Collins, R. L., Brand, H., Karczewski, K. J., Zhao, X., Alföldi, J., Francioli, L. C., ... Genome Aggregation Database Consortium. (2020). A structural variation reference for medical and population genetics. *Nature*, 581(7809), 444–451. <https://doi.org/10.1038/s41586-020-2287-8>
- Del Gobbo, G. F., Yin, Y., Choufani, S., Butcher, E. A., Wei, J., Rajcan-Separovic, E., ... Yuen, R. K. C. (2021). Genomic imbalances in the placenta contribute to poor fetal growth. *Molecular Medicine*, 27, 3. <https://doi.org/10.1186/s10020-020-00253-4>
- Firth, H. V., Richards, S. M., Bevan, A. P., Clayton, S., Corpas, M., Rajan, D., Vooren, S. V., Moreau, Y., Pettett, R. M., & Carter, N. P. (2009). DECIPHER: Database of chromosomal imbalance and phenotype in humans using Ensembl resources. *American Journal of Human Genetics*, 84(4), 524–533. <https://doi.org/10.1016/j.ajhg.2009.03.010>
- Francis, V. A., Abera, A. B., Matjila, M., Millar, R. P., & Katz, A. A. (2014). Kisspeptin regulation of genes involved in cell invasion and angiogenesis in first trimester human trophoblast cells. *PLoS One*, 9(6), e99680. <https://doi.org/10.1371/journal.pone.0099680>
- Girirajan, S., Brkanac, Z., Coe, B. P., Baker, C., Vives, L., Vu, T. H., Shafer, N., Bernier, R., Ferrero, G. B., Silengo, M., Warren, S. T., Moreno, C. S., Fichera, M., Romano, C., Raskind, W. H., & Eichler, E. E. (2011). Relative burden of large CNVs on a range of neurodevelopmental phenotypes. *PLoS Genetics*, 7(11), e1002334. <https://doi.org/10.1371/journal.pgen.1002334>
- Hanna, C. W., Penaherrera, M. S., Saadeh, H., Andrews, S., McFadden, D. E., Kelsey, G., & Robinson, W. P. (2016). Pervasive polymorphic imprinted methylation in the human placenta. *Genome Research*, 26(6), 756–767. <https://doi.org/10.1101/gr.196139.115>
- Kramer, M. S., Platt, R. W., Wen, S. W., Joseph, K. S., Allen, A., Abrahamowicz, M., Blondel, B., Breart, G., for the Fetal/Infant Health Study Group of the Canadian Perinatal Surveillance System, & Fetal/Infant Health Study Group of the Canadian Perinatal Surveillance System. (2001). A new and improved population-based Canadian reference for birth weight for gestational age. *Pediatrics*, 108(2), E35. <https://doi.org/10.1542/peds.108.2.e35>
- Kumar, R., Nagpal, G., Kumar, V., Usmani, S. S., Agrawal, P., & Raghava, G. P. S. (2019). HumCFS: A database of fragile sites in human chromosomes. *BMC Genomics*, 19(9), 985. <https://doi.org/10.1186/s12864-018-5330-5>
- Landrum, M. J., Lee, J. M., Benson, M., Brown, G. R., Chao, C., Chitipiralla, S., Gu, B., Hart, J., Hoffman, D., Jang, W., Karapetyan, K., Katz, K., Liu, C., Maddipati, Z., Malheiro, A., McDaniel, K., Ovetsky, M., Riley, G., Zhou, G., ... Maglott, D. R. (2018). ClinVar: Improving access to variant interpretations and supporting evidence. *Nucleic Acids Research*, 46(D1), D1062–D1067. <https://doi.org/10.1093/nar/gkx1153>
- Lausman, A., Kingdom, J., Gagnon, R., Basso, M., Bos, H., Crane, J., Davies, G., Delisle, M. F., Hudon, L., Menticoglou, S., Mundle, W., Ouellet, A., Pressey, T., Pylpyjuk, C., Roggensack, A., & Sanderson, F. (2013). Intrauterine growth restriction: Screening, diagnosis, and management. *Journal of Obstetrics and Gynaecology Canada*, 35(8), 741–748. [https://doi.org/10.1016/S1701-2163\(15\)30865-3](https://doi.org/10.1016/S1701-2163(15)30865-3)
- Lestou, V. S., & Kalousek, D. K. (1998). Confined placental mosaicism and intrauterine fetal growth. *Archives of Disease in Childhood. Fetal and Neonatal Edition*, 79(3), F223–F226. <https://doi.org/10.1136/fn.79.3.f223>
- Liu, P., Yuan, B., Carvalho, C. M. B., Wuster, A., Walter, K., Zhang, L., ... Lupski, J. R. (2017). An organismal CNV Mutator phenotype restricted to early human development. *Cell*, 168(5), 830–842.e7. <https://doi.org/10.1016/j.cell.2017.01.037>
- Lumbers, E. R., Delforce, S. J., Arthurs, A. L., & Pringle, K. G. (2019). Causes and consequences of the dysregulated maternal renin-angiotensin system in preeclampsia. *Frontiers in Endocrinology*, 10, 563. <https://doi.org/10.3389/fendo.2019.00563>
- MacDonald, J. R., Ziman, R., Yuen, R. K., Feuk, L., & Scherer, S. W. (2014). The database of genomic variants: A curated collection of structural variation in the human genome. *Nucleic Acids Research*, 42, 986–D992. <https://doi.org/10.1093/nar/gkt958>
- Olson, H. E., Shen, Y., Poduri, A., Gorman, M. P., Dies, K. A., Robbins, M., Hundley, R., Wu, B., & Sahin, M. (2012). Micro-duplications of 1q32.1 associated with neurodevelopmental delay. *European Journal of Medical Genetics*, 55(2), 145–150. <https://doi.org/10.1016/j.ejmg.2011.12.008>
- Peñaherrera, M. S., Jiang, R., Avila, L., Yuen, R. K., Brown, C. J., & Robinson, W. P. (2012). Patterns of placental development evaluated by X chromosome inactivation profiling provide a basis to evaluate the origin of epigenetic variation. *Human Reproduction (Oxford, England)*, 27(6), 1745–1753. <https://doi.org/10.1093/humrep/des072>
- Robinson, W. P., Penaherrera, M. S., Jiang, R., Avila, L., Sloan, J., McFadden, D. E., ... von Dadelszen, P. (2010). Assessing the role of placental trisomy in preeclampsia and intrauterine growth restriction. *Prenatal Diagnosis*, 30(1), 1–8. <https://doi.org/10.1002/pd.2409>

- van Echten-Arends, J., Mastenbroek, S., Sikkema-Raddatz, B., Korevaar, J. C., Heineman, M. J., van der Veen, F., & Repping, S. (2011). Chromosomal mosaicism in human preimplantation embryos: A systematic review. *Human Reproduction Update*, 17(5), 620–627. <https://doi.org/10.1093/humupd/dmr014>
- Yuan, V., Hui, D., Yin, Y., Penaherrera, M. S., Beristain, A. G., & Robinson, W. P. (2021). Cell-specific characterization of the placental methylome. *BMC Genomics*, 22(1), 6. <https://doi.org/10.1186/s12864-020-07186-6>
- Zamani Esteki, M., Viltrop, T., Tšuiiko, O., Tiirats, A., Koel, M., Nõukas, M., Žilina, O., Teearu, K., Marjonen, H., Kahila, H., Meekels, J., Söderström-Anttila, V., Suikkari, A. M., Tiitinen, A., Mägi, R., Kõks, S., Kaminen-Ahola, N., Kurg, A., Voet, T., ... Salumets, A. (2019). In vitro fertilization does not increase the incidence of de novo copy number alterations in fetal and placental lineages. *Nature Medicine*, 25(11), 1699–1705. <https://doi.org/10.1038/s41591-019-0620-2>
- Zepeda-Mendoza, C. J., & Morton, C. C. (2019). The iceberg under water: Unexplored complexity of Chromoanagenesis in congenital disorders. *The American Journal of Human Genetics*, 104(4), 565–577. <https://doi.org/10.1016/j.ajhg.2019.02.024>
- Zhang, H., Long, Q., Ling, L., Gao, A., Li, H., & Lin, Q. (2011). Elevated expression of KiSS-1 in placenta of preeclampsia and its effect on trophoblast. *Reproductive Biology*, 11(2), 99–115. [https://doi.org/10.1016/s1642-431x\(12\)60048-5](https://doi.org/10.1016/s1642-431x(12)60048-5)

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Del Gobbo GF, Yuan V, Robinson WP. Confined placental mosaicism involving multiple de novo copy number variants associated with fetal growth restriction: A case report. *Am J Med Genet Part A*. 2021;185A:1908–1912. <https://doi.org/10.1002/ajmg.a.62183>